Unexpectedly, the loss of 53BP1 renders BRCA1-deficient cancer cells resistant to PARPi and ionizing radiation (IR) treatment (6,7), indicating that loss of 53BP1 expression is at least one determinant for how therapeutic resistance may arise in BRCA-mutated cancers. Here, BRCA1 is linked to cancer.